Lung Transplant Failure and Rejection
12
2
3
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
16.7%
2 terminated out of 12 trials
66.7%
-19.8% vs benchmark
17%
2 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
AlloSure Lung Assessment and Metagenomics Outcomes Study
Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
Liquid biopsiEs fOr luNg AllogRaft Damage classificatiOn - LEONARDO
Long Term Follow up of the LTOG Cohort
Clinical Trials in Organ Transplantation Extension Study
Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients
Trajectories of FEV1 After Lung Transplantation
CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation
Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation